Dosing of medications in morbidly obese patients in the intensive care unit setting

[1]  N. Christou,et al.  Antibiotic prophylaxis for surgery in morbidly obese patients. , 1989, Surgery.

[2]  D. Greenblatt,et al.  Cimetidine disposition in obesity. , 1984, The American journal of gastroenterology.

[3]  D. Roden.  Pharmacokinetics of amiodarone: implications for drug therapy. , 1993, The American journal of cardiology.

[4]  A. Geppert,et al.  Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill? , 2002, Critical Care.

[5]  D. Greenblatt,et al.  Alterations in drug distribution and clearance due to obesity. , 1981, The Journal of pharmacology and experimental therapeutics.

[6]  J. Tsikouris,et al.  A Review of Available Fibrin‐Specific Thrombolytic Agents Used in Acute Myocardial Infarction , 2001, Pharmacotherapy.

[7]  D. Greenblatt,et al.  Digoxin disposition in obesity: clinical pharmacokinetic investigation. , 1981, American heart journal.

[8]  E. Gonzalez.  Pharmacokinetics of ranitidine in morbidly obese women. , 1990 .

[9]  Bar Code Documentation of Pharmacotherapy Services in Intensive Care Units , 1996, Pharmacotherapy.

[10]  J. Kehayias,et al.  The meaning and measurement of lean body mass. , 2009, Nutrition reviews.

[11]  W. T. Sawyer,et al.  Calculation of heparin dosage in a morbidly obese woman. , 1989, Clinical pharmacy.

[12]  R. Blouin,et al.  Amikacin pharmacokinetics in morbidly obese patients. , 1980, American journal of hospital pharmacy.

[13]  D. Anderson,et al.  Effect of Patient Weight on the Anticoagulant Response to Adjusted Therapeutic Dosage of Low-Molecular- Weight Heparin for the Treatment ofVenous Thromboembolism , 2001, Pathophysiology of Haemostasis and Thrombosis.

[14]  T. Hua,et al.  Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. , 2009, International journal of clinical pharmacology and therapeutics.

[15]  T. Egan,et al.  Remifentanil Pharmacokinetics in Obese versus Lean Patients , 1998, Anesthesiology.

[16]  J. Dasta,et al.  Variability in dobutamine pharmacokinetics in unstable critically ill surgical patients , 1994, Critical care medicine.

[17]  R. Quenzer,et al.  Pharmacokinetics of Ranitidine in Morbidly Obese Women , 1990, DICP : the annals of pharmacotherapy.

[18]  D. MacGregor,et al.  Pharmacokinetics of Dopamine in Healthy Male Subjects , 2000, Anesthesiology.

[19]  A. Benzer,et al.  Pharmacokinetics of rocuronium bromide in obese female patients. , 1999, European journal of anaesthesiology.

[20]  S. Duffull,et al.  The effect of body weight on dalteparin pharmacokinetics A preliminary study , 2000, European Journal of Clinical Pharmacology.

[21]  M. Chow,et al.  Intravenous Amiodarone: Pharmacology, Pharmacokinetics, and Clinical use , 1996, The Annals of pharmacotherapy.

[22]  G. Cheymol.  Effects of Obesity on Pharmacokinetics , 2000 .

[23]  T. Foster,et al.  Variation in Postoperative Analgesic Requirements in the Morbidly Obese Following Gastric Bypass Surgery , 1982, Pharmacotherapy.

[24]  B. Zahorska-Markiewicz,et al.  Pharmacokinetics of theophylline in obesity. , 1996, International journal of clinical pharmacology and therapeutics.

[25]  W. A. Edwards,et al.  Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients , 2004, European Journal of Clinical Pharmacology.

[26]  W. Jusko,et al.  Procainamide Disposition in Obesity , 1983, Drug intelligence & clinical pharmacy.

[27]  H. Buchwald,et al.  Cefamandole Distribution in Serum, Adipose Tissue, and Wound Drainage in Morbidly Obese Patients , 1986, Drug intelligence & clinical pharmacy.

[28]  R. Matteo,et al.  Pharmacokinetics and Pharmacodynamics of Vecuronium in the Obese Surgical Patient , 1992, Anesthesia and analgesia.

[29]  D. Greenblatt,et al.  Phenytoin disposition in obesity. Determination of loading dose. , 1985, Archives of neurology.

[30]  Robert Raschke,et al.  The Weight-based Heparin Dosing Nomogram Compared with a Standard Care Nomogram , 1993, Annals of Internal Medicine.

[31]  A. Richens,et al.  Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. , 1975, British journal of clinical pharmacology.

[32]  D. Greenblatt,et al.  Lidocaine disposition in obesity. , 1984, The American journal of cardiology.

[33]  M. Bracken,et al.  The Second National Acute Spinal Cord Injury Study. , 1990, Journal of neurotrauma.

[34]  D. Notterman,et al.  Pharmacokinetics of Cardiovascular Drugs in Children , 1994, Clinical pharmacokinetics.

[35]  J. Barré,et al.  Comparative Pharmacokinetics of Intravenous Propranolol in Obese and Normal Volunteers , 1987, Journal of clinical pharmacology.

[36]  Ellis Mj,et al.  Calculation of heparin dosage in a morbidly obese woman. , 1989 .

[37]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[38]  D. Bates,et al.  Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.

[39]  R. L. Yost,et al.  Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. , 1986, Therapeutic drug monitoring.

[40]  U. Buchholz,et al.  Pyrogenic Reactions Associated With Single Daily Dosing of Intravenous Gentamicin , 2000, Infection Control & Hospital Epidemiology.

[41]  L. Bauer,et al.  Vancomycin dosing in morbidly obese patients , 1998, European Journal of Clinical Pharmacology.

[42]  A. Benzer,et al.  Pharmacokinetics of Rocuronium Bromide in Obese Female Patients , 2000 .

[43]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity , 1991, Clinical pharmacology and therapeutics.

[44]  R. Farinotti,et al.  Propofol Infusion for Maintenance of Anesthesia in Morbidly Obese Patients Receiving Nitrous Oxide A Clinical and Pharmacokinetic Study , 1993, Anesthesiology.

[45]  E. Nutescu,et al.  Dosing and Monitoring of Low‐Molecular‐Weight Heparins in Special Populations , 2001, Pharmacotherapy.

[46]  Claude Bouchard,et al.  Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. , 1998, WMJ : official publication of the State Medical Society of Wisconsin.

[47]  F. Donati,et al.  Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium , 1990, Clinical pharmacology and therapeutics.

[48]  H. Winn,et al.  Administration of Methylprednisolone for 24 or 48 Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord Injury Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial , 1997 .

[49]  P. Carrupt,et al.  Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers , 1997 .

[50]  J. B. Caldwell,et al.  Intravenous Ciprofloxacin Dosing in a Morbidly Obese Patient , 1994, The Annals of pharmacotherapy.

[51]  R. L. Yost,et al.  Obesity and post-operative pain. , 1985, Journal of psychosomatic research.

[52]  M. McCarron,et al.  Clinical Pharmacy: Case Studies , 1974 .

[53]  R. Blouin,et al.  Tobramycin pharmacokinetics in morbidly obese patients , 1979, Clinical pharmacology and therapeutics.

[54]  W. Pories,et al.  Prophylactic cefazolin in gastric bypass surgery. , 1981, Surgery.

[55]  W. P. T. James,et al.  Research on obesity. , 1977, Nutrition reviews.

[56]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[57]  A. Traynor,et al.  Aminoglycoside dosing weight correction factors for patients of various body sizes , 1995, Antimicrobial agents and chemotherapy.

[58]  M. Kovacs,et al.  Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. , 1998, Thrombosis research.

[59]  B. Franklin,et al.  Theophylline disposition in obesity , 1978, Clinical pharmacology and therapeutics.

[60]  D. Greenblatt,et al.  Effect of Age, Gender, and Obesity on Midazolam Kinetics , 1984, Anesthesiology.

[61]  M. Kinzig,et al.  Intravenous ciprofloxacin disposition in obesity , 1993, Clinical pharmacology and therapeutics.

[62]  J. Hansen,et al.  Ampicillin and Propylthiouracil Pharmacokinetics in Intestinal Bypass Patients Followed Up to a Year after Operation , 1984, Clinical pharmacokinetics.

[63]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[64]  R. Blouin,et al.  Vancomycin pharmacokinetics in normal and morbidly obese subjects , 1982, Antimicrobial Agents and Chemotherapy.

[65]  M Ariet,et al.  Determination of ideal body weight for drug dosage calculations. , 1983, American journal of hospital pharmacy.